Strides Pharma Science has agreed to acquire and in license a portfolio of branded generic medicines from Sandoz, strengthening its presence across Sub Saharan Africa. The deal, valued at about 12 million dollars, will be executed through its subsidiary Strides Pharma International AG.

The portfolio includes established products across key therapeutic areas such as anti infectives, cardiovascular and dermatology, many of which already generate steady annual sales.

This strategic move is expected to expand Strides’ footprint in major African markets including Ghana, Nigeria and Kenya, while opening new cross selling opportunities.

The company aims to leverage Sandoz’s established brands to deepen market access and improve availability of affordable medicines in the region. The acquisition also aligns with Strides’ broader strategy to scale its branded generics business in emerging markets and enhance its commercial reach.

For Sandoz, the agreement reflects continued portfolio optimisation as it sharpens focus on its core global generics and biosimilars operations.